| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 06/28/2001 | WO2001046261A1 Method for treating inflammation |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046256A2 Vesicle trafficking proteins |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046232A2 Soluble interleukin-20 receptor |
| 06/28/2001 | WO2001046195A1 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| 06/28/2001 | WO2001046185A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046180A2 Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same |
| 06/28/2001 | WO2001046176A2 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046168A1 Tryptase inhibitors |
| 06/28/2001 | WO2001046166A2 Partially saturated calcium channel blockers |
| 06/28/2001 | WO2001046164A1 Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidinones as antibacterials |
| 06/28/2001 | WO2001046151A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046128A2 Tryptase inhibitors |
| 06/28/2001 | WO2001046110A2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| 06/28/2001 | WO2001045751A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | WO2001045749A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | WO2001045741A2 Methods for preparing pharmaceutical formulations |
| 06/28/2001 | WO2001045730A2 Tweak receptor |
| 06/28/2001 | WO2001045721A1 Agent which is anti-adhesive in relation to the pathogenic flora of the skin |
| 06/28/2001 | WO2001045717A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | WO2001045716A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor |
| 06/28/2001 | WO2001045713A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045702A1 SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
| 06/28/2001 | WO2001045697A1 Skin external agents and drugs |
| 06/28/2001 | WO2001045688A2 Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients |
| 06/28/2001 | WO2001045679A2 Use of chemotherapeutic agents for topical treatment |
| 06/28/2001 | WO2001045668A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 06/28/2001 | WO2001045664A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/28/2001 | WO2001045663A2 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 06/28/2001 | WO2001045661A2 Cosmetic and/or pharmaceutical preparations |
| 06/28/2001 | WO2001045650A2 Cosmetic use of the residues from wine production |
| 06/28/2001 | WO2001045648A2 Use of a vaccinium-type extract as an anti-glycation agent |
| 06/28/2001 | WO2001045645A1 Chitosan biopolymer for the topical delivery of active agents |
| 06/28/2001 | WO2001005974A9 The il-1l1 gene and polypeptide products |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000068247A3 Serine proteases |
| 06/28/2001 | WO2000066731A3 Recombinant laminin 5 |
| 06/28/2001 | WO2000066104A3 Ace-2 inhibiting compounds and methods of use thereof |
| 06/28/2001 | WO2000063236A3 Adhesion modulatory peptides and methods for use |
| 06/28/2001 | WO2000061180A3 Products and methods for treating ptp lar related diseases |
| 06/28/2001 | WO2000055321A3 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 06/28/2001 | DE19960640A1 Neue Stromelysin Inhibitoren New stromelysin inhibitors |
| 06/28/2001 | DE19958693A1 Verfahren und Zusammensetzungen zur Herstellung von Zelltransplantaten Methods and compositions for the production of cell transplants |
| 06/28/2001 | DE19957065A1 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 06/28/2001 | CA2717246A1 Use of quinoline and quinolizinone derivatives as chemotherapeutic agents |
| 06/28/2001 | CA2399584A1 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | CA2395435A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | CA2395406A1 Method for treating inflammation |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395191A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| 06/28/2001 | CA2395136A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | CA2395113A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | CA2395109A1 1,1-disubstituted ethylene adhesive compositions containing polydimethylsiloxane |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2394901A1 Chitosan biopolymer for the topical delivery of active agents |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2394604A1 Substituted acylhydroxamic acids and method of reducing tnf.alpha. levels |
| 06/28/2001 | CA2394330A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a na+/h+ exchanger inhibitors, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | CA2394139A1 Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same |
| 06/28/2001 | CA2394049A1 Vesicle trafficking proteins |
| 06/28/2001 | CA2394015A1 Tweak receptor |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393837A1 Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392127A1 Tryptase inhibitors |
| 06/28/2001 | CA2392121A1 Tryptase inhibitors |
| 06/28/2001 | CA2389482A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 06/28/2001 | CA2363837A1 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/27/2001 | EP1110953A1 Quinazoline derivatives |
| 06/27/2001 | EP1110555A1 Antiadhesive agent for the pathogen flora of the skin |
| 06/27/2001 | EP1110539A1 Use of 3,3',5,5'-tetrahehydroxystilbene as a glycation inhibitor |
| 06/27/2001 | EP1110537A2 Cosmetic composition comprising N-ethoxycarbonyl-4-aminophenol and arbutin or its derivatives and/or ellagic acid or its derivatives |
| 06/27/2001 | EP1109919A2 Rationally designed heparinases derived from heparinase i and ii |
| 06/27/2001 | EP1109909A2 Grf analogs with increased biological potency |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109905A1 Genes encoding for the human and murine death inducer-obliterator-1 |
| 06/27/2001 | EP1109903A2 Human rna-associated proteins |
| 06/27/2001 | EP1109829A1 Human latent transforming growth factor beta binding protein 3 |
| 06/27/2001 | EP1109810A1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/27/2001 | EP1109804A1 Chemokine receptor antagonists and methods of use therefor |
| 06/27/2001 | EP1109803A1 Substituted imidazoles having cytokine inhibitory activity |
| 06/27/2001 | EP1109790A1 1, 2, 4-triazole-3-thione compounds |
| 06/27/2001 | EP1109777A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2001 | EP1109573A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa |
| 06/27/2001 | EP1109570A2 Method of modulating memory effector t-cells and compositions |
| 06/27/2001 | EP1109559A2 Inhibition of pathogenic processes related to tissue trauma |
| 06/27/2001 | EP1109556A2 New pharmaceutical uses for nos inhibitors |
| 06/27/2001 | EP1109555A1 Novel angiogenesis inhibitors |
| 06/27/2001 | EP1109554A2 Pipecolic acid derivatives for vision and memory disorders |
| 06/27/2001 | EP1109529A1 Lipid extract of the skeletonema algae |
| 06/27/2001 | EP1109527A2 Cosmetic composition |
| 06/27/2001 | EP0862564A4 Photoactivatable compounds for the prevention of intimal hyperplasia and other diseases |
| 06/27/2001 | CN1301298A Methods for prevention and treatment of cancer |
| 06/27/2001 | CN1301271A Methods for identifying inducers and inhibitors of propteolytic antibodies, compositions and their uses |